Kim Mijin, Kang Seungmin, Oh Seikwan
Department of Molecular Medicine, School of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
Biomol Ther (Seoul). 2025 Jan 1;33(1):106-116. doi: 10.4062/biomolther.2024.049. Epub 2024 Oct 11.
A previously reported study highlighted the neuroprotective potential of the novel benzylideneacetophenone derivative, JC3, in mice. In pursuit of compounds with even more robust neuroprotective and anti-inflammatory properties compared to JC3, we synthesized substituted 1,3-diphenyl-2-propen-1-ones based on chalcones. Molecular modeling studies aimed at discerning the chemical structural features conducive to heightened biological activity revealed that JCII-8,10,11 exhibited the widest HOMOLUMO gap within this category, indicating facile electron and radical transfer between HOMO and LUMO in model assessments. From the pool of synthesized compounds, JCII-8,10,11 were selected for the present investigation. The biological assays involving JCII-8,10,11 demonstrated their concentration-dependent suppression of iNOS and COX-2 protein levels, alongside various cytokine mRNA expressions in LPS-induced murine microglial BV2 cells. Furthermore, western blot analyses were conducted to investigate the MAPK pathways and NF-κB/p65 nuclear translocation. These evaluations conclusively confirmed the inflammatory inhibition effects in both and inflammation models. These findings establish JCII-8,10,11 as potent anti-inflammatory agents, hindering inflammatory mediators and impeding NF-κB/p65 nuclear translocation via JNK and ERK MAPK phosphorylation in BV2 cells. The study positions them as potential therapeutics for inflammation-related conditions. Additionally, JCII-11 exhibited greater activity compared to other tested JCII compounds.
先前报道的一项研究强调了新型苄叉丙酮衍生物JC3对小鼠的神经保护潜力。为了寻找比JC3具有更强神经保护和抗炎特性的化合物,我们基于查尔酮合成了取代的1,3-二苯基-2-丙烯-1-酮。旨在识别有助于提高生物活性的化学结构特征的分子模型研究表明,JCII-8、10、11在此类化合物中表现出最宽的HOMO-LUMO能隙,这表明在模型评估中,HOMO和LUMO之间的电子和自由基转移较为容易。从合成的化合物中,选择了JCII-8、10、11进行本研究。涉及JCII-8、10、11的生物学测定表明,它们在脂多糖诱导的小鼠小胶质细胞BV2中,对诱导型一氧化氮合酶(iNOS)和环氧化酶-2(COX-2)蛋白水平以及各种细胞因子mRNA表达具有浓度依赖性抑制作用。此外,进行了蛋白质免疫印迹分析以研究丝裂原活化蛋白激酶(MAPK)途径和核因子-κB(NF-κB)/p65核转位。这些评估最终证实了在体内和体外炎症模型中的炎症抑制作用。这些发现确立了JCII-8、10、11为有效的抗炎剂,它们通过BV2细胞中的c-Jun氨基末端激酶(JNK)和细胞外信号调节激酶(ERK) MAPK磷酸化来阻碍炎症介质并阻止NF-κB/p65核转位。该研究将它们定位为炎症相关疾病的潜在治疗药物。此外,与其他测试的JCII化合物相比,JCII-11表现出更大的活性。